Skip to Main Content

Paper Details

A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Sci Immunol
50
2021
-, 3M-052, Anti-, CD14, CD14+, CD14+CD16++ intermediate blood monocytes, CD16, CD16++, CD4, CD4+, CD8+, CD8+ T cell, CoV-2, Fractalkine, MCP-1, RBD, RBD antibody, RBD-specific plasma cells, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 virus, T cell, TLR, TRAIL, Th1, Th1 biased CD4+, alum, human, lung inflammation, monocyte, plasma, receptor, rhesus macaques, yeast
Author NameAffiliation
Kirk A EasleyEmory University
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Alessandro SetteUniversity of California, San Diego (university of california san diego)
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Alessandro SetteUniversity of California, San Diego (university of california san diego)
Celia C LaBrancheDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham
Xiaoying ShenDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham
David C MontefioriBaylor College of Medicine
David C MontefioriDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center Durham
Rafick-Pierre SekalyYerkes National Primate Research Center at Emory University
Rafick-Pierre SekalyEmory University
Mark A Tomai
Mehul S SutharYerkes National Primate Research Center at Emory University
Mehul S SutharEmory Vaccine Center at Emory University
Mehul S SutharCenters for Childhood Infections and Vaccines Children's Healthcare of Atlanta and Emory University
Pamela A KozlowskiLouisiana State University Health Sciences Center
Sudhir Pai KasturiYerkes National Primate Research Center at Emory University
Sudhir Pai KasturiEmory University
  • 1 - 18

Datasets

Release 1.2